Search results for "Pool"

showing 10 items of 238 documents

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in pati…

2015

Aim: Breast International Group (BIG) 2-98 is a randomised phase III trial that tested the effect of adding docetaxel, either in sequence to or in combination with anthracycline-based adjuvant chemotherapy, in women with node-positive breast cancer (BC). Here, we present the 10-year final trial safety and efficacy analyses. We also report an exploratory analysis on the predictive value of Ki67 for docetaxel efficacy, in the BIG 2-98 and using a pooled analysis of three other randomised trials. Patients and methods: 2887 patients were randomly assigned in a 2 x 2 trial design to one of four treatments. The primary objective was to evaluate the overall efficacy of docetaxel on disease free su…

OncologyAdultAdjuvant taxanesCancer Researchmedicine.medical_specialtyAnthracyclinemedicine.medical_treatmenteducationBreast NeoplasmsDocetaxelDisease-Free SurvivalPooled analysisBreast cancerBreast cancerPredictive Value of TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansIn patientAnthracyclinesOestrogen receptorProspective StudiesAgedER positivebusiness.industryMiddle Agedmedicine.diseaseImmunohistochemistryPooled analysisKi-67 AntigenOncologyDocetaxelBreast international groupChemotherapy AdjuvantFemaleTaxoidsbusinessAdjuvantKi67medicine.drug
researchProduct

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy

2010

Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients eligible for second-line treatment is scarce. The aim of this study was to assess the prognostic role of a number of routinely collected clinical variables and to provide a summary index to discriminate patients according to probability of survival.Methods: individual data from nine randomised trials of second-line treatment in advanced NSCLC were analysed. Primary end-point was overall survival (OS). Cox model, stratified by trial, was used for multivariate analyses, and a prognostic index was provided and validated according to an internal/external procedure.Results: Out of 1239 patients, 119…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisLung NeoplasmsWEEKLY DOCETAXELIRINOTECANCOMBINATION CHEMOTHERAPYAntineoplastic AgentsERLOTINIBPrognostic factorsNSCLCTHERAPYPooled analysisPLUS GEMCITABINEInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansStage (cooking)Lung cancerEVERY 3 WEEKSAgedNeoplasm StagingRandomized Controlled Trials as TopicAged 80 and overPerformance statusProportional hazards modelbusiness.industryAge FactorsCombination chemotherapyPHASE-III TRIALMiddle Agedmedicine.diseasePrognosisTreatment OutcomeOncologyMeta-analysisPrognostic scoreCOMPARING DOCETAXELSecond-line treatmentAdenocarcinomaFemalebusinessEpidemiologic MethodsNon-small-cell lung cancerEuropean Journal of Cancer
researchProduct

Occupation and Risk of Non-Hodgkin Lymphoma and Its Subtypes: A Pooled Analysis from the InterLymph Consortium

2016

Background: Various occupations have been associated with an elevated risk of non-Hodgkin lymphoma (NHL), but results have been inconsistent across studies. Objectives: We investigated occupational risk of NHL and of four common NHL subtypes with particular focus on occupations of a priori interest. Methods: We conducted a pooled analysis of 10,046 cases and 12,025 controls from 10 NHL studies participating in the InterLymph Consortium. We harmonized the occupational coding using the 1968 International Standard Classification of Occupations (ISCO-1968) and grouped occupations previously associated with NHL into 25 a priori groups. Odds ratios (ORs) adjusted for center, age, and sex were det…

OncologyAdultMalemedicine.medical_specialtyAdolescentHealth Toxicology and MutagenesisMEDLINEReviewBarbering03 medical and health sciences0302 clinical medicineimmune system diseasesRisk FactorsInternal medicinehemic and lymphatic diseasesmedicineHumans030212 general & internal medicineAgedAged 80 and overbusiness.industryExtramuralPublic healthLymphoma Non-HodgkinPublic Health Environmental and Occupational HealthCase-control studyAgricultureMiddle Agedmedicine.disease030210 environmental & occupational healthSeguretat en el treballLymphomaMalaltia de HodgkinOccupational DiseasesPooled analysisMeta-analysisCase-Control StudiesTextile IndustryHodgkin lymphomaIndustrial safetyFemaleHodgkin's diseasebusinessOccupation - non-hodgkin lymphomaEnvironmental Health Perspectives
researchProduct

Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advan…

2014

3575 Background: After the use of preoperative radiotherapy and TME, survival of LARC has reached a plateau. More effective therapies, predictive/prognostic factors for treatment selection and vali...

OncologyCancer Researchmedicine.medical_specialtyChemotherapyPreoperative radiotherapybusiness.industryColorectal cancermedicine.medical_treatmentLocally advancedmedicine.diseaseSurgeryPooled analysisOncologyInternal medicinemedicinesense organsbusinessChemoradiotherapyJournal of Clinical Oncology
researchProduct

Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis o…

2013

e20028 Background: Adjuvant high-dose interferon (HDI) treatment of patients (pts) with malignant melanoma (MM) consists of 4 weeks intravenous (IV) induction with 20 MU/m² interferon (IFN) alpha 2b followed by 11 months of 10 Mio IU/m² IFN subcutaneously (sc). It is unclear whether both parts of the regimen are mandatory for the efficacy of HDI treatment. The adjuvant phase III trials DeCOG MM-ADJ-5 and the Italian Melanoma Intergroup (IMI) trial evaluated intermittent IV HDI (iHDI) regimens as compared to standard HDI. In both trials, the experimental arm consisted of iHDI for 3 or 4 cycles, respectively. To gain more insight into the role of iHDI in the adjuvant setting we performed a p…

OncologyCancer Researchmedicine.medical_specialtyPhase iii trialsbusiness.industryMelanomamedicine.medical_treatmentAlpha interferonmedicine.diseasePooled analysisOncologyInterferonInternal medicineImmunologymedicineStage (cooking)businessAdjuvantmedicine.drugJournal of Clinical Oncology
researchProduct

A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence doe…

2015

It is still uncertain if targeted therapy-based regimens in advanced gastric cancer actually produce survival benefit. To shed light on this important question, we performed a systematic review and meta-analyses on each relevant targeted-pathway. By searching literature databases and proceedings of major cancer meetings in the time-frame 2005–2014, 22 randomized clinical trials exploring targeted therapy for a total of 7022 advanced gastric cancer patients were selected and included in the final analysis. Benefit was demonstrated for antiangiogenic agents in terms of overall survival (HR 0.759; 95%CI 0.655–0.880; p < 0.001). Conversely no benefit was found for EGFR pathway (HR 1.077; 95%…

OncologyCancer Researchmedicine.medical_specialtyReceptor ErbB-2medicine.medical_treatmentAngiogenesis InhibitorsBioinformaticsTargeted therapylaw.inventionTargeted therapyRandomized controlled trialTargeted pathwayStomach NeoplasmlawStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMeta-analysiMolecular Targeted TherapySystemic chemotherapySurvival analysisRandomized Controlled Trials as TopicPharmacologyAntineoplastic Combined Chemotherapy Protocolbusiness.industryCancerAdvanced gastric cancermedicine.diseaseSurvival AnalysisErbB ReceptorsAngiogenesiPooled analysisOncologyTolerabilityMeta-analysisClinical StudyMolecular MedicineReceptor Epidermal Growth FactorSurvival AnalysiRandomized clinical trialbusinessGastric cancerAngiogenesis InhibitorHuman
researchProduct

Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies

2016

Purpose Identifying patients at high risk of progression and early death among those with high-tumor-burden follicular lymphoma (FL) is unsatisfactory with current prognostic models. This study aimed to determine the prognostic impact of the total metabolic tumor volume (TMTV) measured at baseline with [18F]fluorodeoxyglucose/positron emission tomography-computed tomography ([18F]FDG/PET-CT) scans and its added value to these models. Patients and Methods A pooled analysis was performed by using patient data and centrally reviewed baseline PET-CT scans for 185 patients with FL who were receiving immunochemotherapy within three prospective trials. TMTV was computed by using the 41% maximum st…

OncologyFluorodeoxyglucoseCancer Researchmedicine.medical_specialtybusiness.industryFollicular lymphomaStandardized uptake valueMetabolic tumor volumemedicine.disease030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinePooled analysisInternational Prognostic IndexOncology030220 oncology & carcinogenesisInternal medicineMedicinePositron emissionStage (cooking)businessNuclear medicinemedicine.drugJournal of Clinical Oncology
researchProduct

Prevalence of HPV infection in racial-ethnic subgroups of head and neck cancer patients

2017

Abstract The landscape of human papillomavirus (HPV) infection in racial/ethnic subgroups of head and neck cancer (HNC) patients has not been evaluated carefully. In this study, a meta-analysis examined the prevalence of HPV in HNC patients of African ancestry. Additionally, a pooled analysis of subject-level data was also performed to investigate HPV prevalence and patterns of p16 (CDNK2A) expression amongst different racial groups. Eighteen publications (N = 798 Black HNC patients) were examined in the meta-analysis, and the pooled analysis included 29 datasets comprised of 3129 HNC patients of diverse racial/ethnic background. The meta-analysis revealed that the prevalence of HPV16 was h…

OncologyOROPHARYNGEAL CANCERHPVCancer Researchmedicine.medical_specialtyEthnic groupUNITED-STATESOriginal Manuscript03 medical and health sciences0302 clinical medicineInternal medicinemedicineP16 IMMUNOHISTOCHEMISTRYHuman papillomavirus030223 otorhinolaryngologyEPSTEIN-BARR-VIRUSE6/E7 MESSENGER-RNAAFRICAN-AMERICANSHUMAN-PAPILLOMAVIRUS TYPE-16IMPROVED SURVIVALbusiness.industryPOTENTIALLY MALIGNANT DISORDERSHead and neck cancerHPV infectionCancerOrvostudományokGeneral Medicinemedicine.diseaseRacial ethnic3. Good healthPooled analysis030220 oncology & carcinogenesisSmoking statusSettore MED/31 - OTORINOLARINGOIATRIASQUAMOUS-CELL CARCINOMAEgészségtudományokbusiness
researchProduct

A Pooled Analysis of Extremely Low-Frequency Magnetic Fields and Childhood Brain Tumors

2010

Pooled analyses may provide etiologic insight about associations between exposure and disease. In contrast to childhood leukemia, no pooled analyses of childhood brain tumors and exposure to extremely low-frequency magnetic fields (ELF-MFs) have been conducted. The authors carried out a pooled analysis based on primary data (1960–2001) from 10 studies of ELF-MF exposure and childhood brain tumors to assess whether the combined results, adjusted for potential confounding, indicated an association. The odds ratios for childhood brain tumors in ELF-MF exposure categories of 0.1–<0.2 μT, 0.2–<0.4 μT, and ≥0.4 μT were 0.95 (95% confidence interval: 0.65, 1.41), 0.70 (95% CI: 0.40, 1.22), and 1.1…

Oncologymedicine.medical_specialtyNeoplasms Radiation-InducedChildhood leukemiaEpidemiologyBrain tumorGlobal HealthCentral nervous system diseaseElectromagnetic FieldsRisk FactorsInternal medicineEpidemiologymedicineHumansChildBrain Neoplasmsbusiness.industryIncidenceConfoundingOdds ratiomedicine.diseaseConfidence intervalSurgeryMeta-analysisbusinessSystematic Reviews and Meta- and Pooled AnalysesAmerican Journal of Epidemiology
researchProduct

Metastatic site location may influence the diagnostic accuracy of plasma EGFR-mutation testing in NSCLC: A pooled analysis

2017

Oncologymedicine.medical_specialtyPooled analysisOncologySite locationEgfr mutationbusiness.industryInternal medicinemedicineDiagnostic accuracyHematologybusinessAnnals of Oncology
researchProduct